Thursday, January 22, 2026 1/22/2026

Analysis of E-selectin Ligands of Human Acute Leukemia Cells and their Biology in Leukemogenesis

Award Number: U01CA225730
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/17/2019
PERIOD OF PERFORMANCE END DATE: 06/30/2025

Group Awards By:

View Award Description

Analysis of E-selectin Ligands of Human Acute Leukemia Cells and their Biology in Leukemogenesis - ABSTRACT: The tetrasaccharide known as “sialylated Lewis X” (sLeX; CD15s) is the prototypical binding determinant for E- selectin (CD62E), a Ca++-dependent lectin expressed on vascular endothelial cells. Through investigations described herein, we aim to unveil how this structure, and the underlying glycosyltransferases (GTs) controlling its biosynthesis, mediate(s) human leukemogenesis. The sLeX motif can be presented on cell surfaces on protein (i.e., glycoprotein) and/or lipid (i.e., glycolipid) scaffolds, and these glycoconjugates (known as “E-selectin ligands”) program shear-resistant adhesion to endothelial cells. E-selectin is typically not displayed on resting vascular endothelial cells, and its expression is induced by inflammatory cytokines such as TNF and IL-1. How- ever, conspicuously, E-selectin is constitutively expressed on bone marrow (BM) sinusoidal vessels where it is known to play a key role in mediating migration of circulating cells to BM, a process critical to blood cell recovery following hematopoietic stem cell transplantation (HSCT). Beyond its role in recruiting hematopoietic stem/pro- genitor cells (HSPCs) to BM, it is well-known that E-selectin expression on marrow microvessels serves a fun- damental role in creation of hematopoietic growth-promoting microenvironments, collectively known as “vascular niches”. Studies from our laboratory have shown that human HSPCs express a variety of E-selectin ligands, and we have also observed that leukemic blasts characteristically express E-selectin ligands. We hypothesize that engagement of E-selectin ligands on human acute leukemia cells programs efficient BM metastasis and also enables niche lodgment, serving to displace resident HSPCs from their proper growth microenvironment and thereby promoting leukemic cell proliferation. In this proposal, using E-selectin binding assays under both static and fluid shear conditions, together with complementary techniques in flow cytometry and western blotting, we will analyze the E-selectin binding activity of leukemia cells isolated from blood and BM of patients with acute leukemias. We will identify the pertinent sLeX-bearing glycoconjugates among the different types of human leu- kemia cells, measure the ability of such glycoconjugates to engage E-selectin, and determine how expression of Golgi GTs shape creation of sLeX modifications among the different E-selectin ligands. This information will be integrated with various biochemical approaches including metabolic inhibition of glycosylation and cell surface glycoengineering to custom-modify sLeX display to assess the extent to which sLeX presentation on a specific protein and/or lipid scaffold licenses E-selectin binding among blasts from various subtypes of human acute leukemias, and the impact of the relevant E-selectin receptor/ligand interaction(s) in leukemia cell biology. The results of proposed studies will be key to elucidating the glycobiology of leukemogenesis, and should also pro- vide fundamental insights for establishing novel strategies to treat acute leukemias by selectively interrupting sLeX expression and/or E-selectin ligand-mediated processes, and for potential therapy/prognosis stratification schemas based on sLeX levels and/or the expression of distinct E-selectin ligands on acute leukemia cells. Relevance: Acute leukemia arises because abnormal white cell precursors proliferate within special growth zones within the bone marrow. There is increasing evidence that these growth zones are created by the display of particular sugar molecules on the surface of blood cells that act like Velcro to anchor the cells to marrow vessels. This research project will study these sugar structures and how they are made, with anticipation that information obtained will pave the way for more effective therapies for acute leukemias and may also allow for more precise identification of patients needing more intensive treatment and/or closer monitoring.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = -$201,152 )
2026	2023	FLORIDA INTERNATIONAL UNIVERSITY	11200 SW 8TH ST	MIAMI	FL	33199	MIAMI-DADE	USA	Cancer Biology Research	000	5	12/5/2025	NON-COMPETING CONTINUATION	-$201,152
														Subtotal = -$201,152

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2023	FLORIDA INTERNATIONAL UNIVERSITY	11200 SW 8TH ST	MIAMI	FL	33199	MIAMI-DADE	USA	Cancer Biology Research	000	5	2/19/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $601,611 )
2023	2023	FLORIDA INTERNATIONAL UNIVERSITY	11200 SW 8TH ST	MIAMI	FL	33199	MIAMI-DADE	USA	Cancer Biology Research	001	5	7/3/2023	NON-COMPETING CONTINUATION	$601,611
2023	2022	FLORIDA INTERNATIONAL UNIVERSITY	11200 SW 8TH ST	MIAMI	FL	33199	MIAMI-DADE	USA	Cancer Biology Research	000	4	1/17/2023	NON-COMPETING CONTINUATION	$0
														Subtotal = $601,611

Issue Date FY: 2022 ( Subtotal = $601,611 )
2022	2022	FLORIDA INTERNATIONAL UNIVERSITY	11200 SW 8TH ST	MIAMI	FL	33199	MIAMI-DADE	USA	Cancer Biology Research	001	4	6/15/2022	NON-COMPETING CONTINUATION	$601,611
2022	2021	FLORIDA INTERNATIONAL UNIVERSITY	11200 SW 8TH ST	MIAMI	FL	33199	MIAMI-DADE	USA	Cancer Biology Research	000	3	3/25/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $601,611

Issue Date FY: 2021 ( Subtotal = $596,316 )
2021	2021	FLORIDA INTERNATIONAL UNIVERSITY	11200 SW 8TH ST	MIAMI	FL	33199	MIAMI-DADE	USA	Cancer Biology Research	001	3	9/17/2021	SUPPLEMENT FOR EXPANSION	$166,667
2021	2021	FLORIDA INTERNATIONAL UNIVERSITY	11200 SW 8TH ST	MIAMI	FL	33199	MIAMI-DADE	USA	Cancer Biology Research	000	3	6/30/2021	NON-COMPETING CONTINUATION	$429,649
														Subtotal = $596,316

Issue Date FY: 2020 ( Subtotal = $613,888 )
2020	2020	FLORIDA INTERNATIONAL UNIVERSITY	11200 SW 8TH ST	MIAMI	FL	33199	MIAMI-DADE	USA	Cancer Biology Research	000	2	7/30/2020	NON-COMPETING CONTINUATION	$613,888
														Subtotal = $613,888

Issue Date FY: 2019 ( Subtotal = $625,763 )
2019	2019	FLORIDA INTERNATIONAL UNIVERSITY	11200 SW 8TH ST	MIAMI	FL	33199	MIAMI-DADE	USA	Cancer Biology Research	000	1	7/17/2019	NEW	$625,763
														Subtotal = $625,763

Grand Total All Awards = $2,838,037

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Analysis of E-selectin Ligands of Human Acute Leukemia Cells and their Biology in Leukemogenesis

Award Number: U01CA225730

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/17/2019

PERIOD OF PERFORMANCE END DATE: 06/30/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer